{
    "body": "List adenosine A2A receptor antagonists that are used for Parkinson's disease treatment.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23748382", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20182024", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24687255", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15298067", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22585137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25175961", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15974638", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23483627", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16004599", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23642267"
    ], 
    "ideal_answer": [
        "Istradefylline and preladenant are adenosine A2A receptor antagonists that are used for Parkinson's disease treatment."
    ], 
    "exact_answer": [
        [
            "istradefylline"
        ], 
        [
            "preladenant"
        ]
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058917", 
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010300", 
        "http://www.disease-ontology.org/api/metadata/DOID:14330"
    ], 
    "type": "list", 
    "id": "54fc9b236ad7dcbc12000005", 
    "snippets": [
        {
            "offsetInBeginSection": 177, 
            "offsetInEndSection": 323, 
            "text": "Adenosine A2A antagonists, such as istradefylline, improve motor function in PD, but their effect on cognitive impairment has not been determined.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23748382", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 862, 
            "offsetInEndSection": 995, 
            "text": "Both istradefylline and preladenant have demonstrated moderate efficacy in reducing off time in PD patients with motor fluctuations. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22585137", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1067, 
            "offsetInEndSection": 1310, 
            "text": " The available data also suggest that caffeine can improve the motor deficits of PD and that adenosine A2A receptor antagonists such as istradefylline reduces OFF time and dyskinesia associated with standard 'dopamine replacement' treatments. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20182024", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 955, 
            "offsetInEndSection": 1228, 
            "text": "Istradefylline (KW-6002) is the first of several adenosine A2A receptor antagonists in development for PD to advance to phase III clinical trials. Initial studies indicate that in patients with motor fluctuations on levodopa, addition of istradefylline reduces 'off' time. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15974638", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 858, 
            "offsetInEndSection": 1240, 
            "text": "These include alpha2 adrenergic receptor antagonists (eg, fipamezole), adenosine A2A receptor antagonists (eg, istradefylline), AMPA receptor antagonists (eg, talampanel), neuronal synchronization modulators (eg, levetiracetam) and agents that interact with serotonergic systems such as 5-hydroxytryptamine (5-HT)1A agonists (eg, sarizotan) and 5-HT2A antagonists (eg, quetiapine). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15298067", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 266, 
            "text": "BACKGROUND: We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinsons disease patients with motor complications in Japan.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23483627", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 99, 
            "text": "Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinsons disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16004599", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 100, 
            "text": "Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16004599", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 431, 
            "offsetInEndSection": 606, 
            "text": "In this article, the author discusses the potential role of A2A adenosine receptor antagonists in the treatment of Parkinson's disease through the evaluation of istradefylline", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23642267", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 141, 
            "text": "Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23642267", 
            "endSection": "title"
        }
    ]
}